ProfileGDS5678 / 1418205_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 18% 45% 60% 46% 16% 14% 16% 14% 63% 67% 50% 53% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0540544
GSM967853U87-EV human glioblastoma xenograft - Control 22.4428618
GSM967854U87-EV human glioblastoma xenograft - Control 33.049445
GSM967855U87-EV human glioblastoma xenograft - Control 43.5671960
GSM967856U87-EV human glioblastoma xenograft - Control 53.0217946
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4387616
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3791914
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3857916
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3173714
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7748763
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0576967
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1611650
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3065153
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8644565